← Back to blog

FDA Requires a New Eye Warning on All GLP-1 Medications: What to Know About NAION

On November 9, 2026, the FDA announced that it is requiring a new warning on every GLP-1 receptor agonist about a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION. The labeling change covers the whole drug class, including semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide products. Here is what the agency found and how to put it in proportion.

What NAION is

NAION is a rare condition in which damage to the optic nerve can cause sudden vision loss. It occurs in people who have never taken a GLP-1. FDA noted that its risk factors often overlap with conditions that are common in people taking these drugs, which made individual adverse event reports hard to interpret.

What the FDA looked at

  • A meta-analysis of 126 clinical trials covering 134,253 patients. It found 15 probable NAION events: 10 in people on a GLP-1, 5 on placebo, and none in people on other glucose-lowering drugs. That works out to 6.4 events per 100,000 patient-years on a GLP-1 versus 3.8 for comparators.
  • A real-world cohort study of adults with type 2 diabetes who started a GLP-1 or another diabetes drug between 2019 and 2024. Rates were similar across groups, from 26 to 32 per 100,000 patient-years. Compared with SGLT-2 inhibitors, the difference was not statistically significant. Compared with DPP-4 inhibitors, it was (hazard ratio 1.43).
  • Published observational studies. The rigorous ones consistently reported a higher risk in people starting a GLP-1 than in those starting DPP-4 or SGLT-2 inhibitors.
  • Animal data did not identify a mechanism that would explain the risk.

NAION cases have been reported with every marketed GLP-1 product. FDA concluded there is a potential increased risk and is adding the warning to the Warnings and Precautions section of each label.

Putting the numbers in proportion

The absolute risk is small. In the trial meta-analysis, the gap was roughly 2.6 extra cases per 100,000 patient-years, and it rests on only 15 events, so the estimate is imprecise. The label change describes a potential increased risk. It does not say these drugs cause NAION in most users, and it is not a reason to stop a medication on your own. Stopping can have its own consequences for weight and blood sugar.

What to do

  • Treat sudden vision changes in one eye as urgent. Blurring, a dark patch or loss of part of your field of vision calls for same-day eye care or emergency care.
  • Tell your prescriber and eye doctor if you have had NAION or another optic nerve problem before.
  • Ask about regular eye exams, especially if you have diabetes.
  • Talk to your provider before changing or stopping a medication because of this warning.
  • If you keep a symptom log, note any vision changes with the date.

This article summarizes an FDA drug safety communication and related reporting for general information and is not medical advice. Content was rephrased for compliance. If you experience sudden vision loss, seek medical care immediately.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment protocol.